Results 61 to 70 of about 36,176 (202)

Evaluating the appropriateness of fresh frozen plasma transfusions in two tertiary teaching hospitals

Transfusion Medicine, EarlyView.
Abstract Background Despite efforts to standardise practice using evidence‐based guidelines, fresh frozen plasma (FFP) remains the blood component most frequently prescribed inappropriately. This study assessed the appropriateness of FFP transfusion in two tertiary teaching hospitals and analysed the characteristics of appropriate and inappropriate ...
Jongmin Kim, Kae Lyang Koo, Hyun‐Ji Lee, Hyung‐Hoi Kim   +3 more
wiley   +1 more source

Rare Presentation of Refractory Thrombotic Thrombocytopenic Purpura: Jejunal Stricture

International Journal of Hematology-Oncology and Stem Cell Research, 2017
Thrombotic thrombocytopenic purpura is a rare thrombotic disease characterized by episodes of thrombocytopenia and microangiopathic hemolytic anemia due to disseminated microvascular thrombosis.
Prabath K. Abeysundara, Inoshi Atukorala, K. P. C. Dalpatadu, Karthiha Balendran, M. D. S. A. Dilrukshi, G M O Fernando   +5 more
doaj  

Caplacizumab in the Treatment of Patients with Recurrent Thrombotic Thrombocytopenic Purpura (TTP) [PDF]

Documenta Haematologica
We report two cases of recurrent thrombotic thrombocytopenic purpura, both patients without significant personal pathological antecedents, in which the evolution was favorable following the association of Caplacizumab with the classic treatment with ...
Mihaela-Sabrina HERDEA, Adela-Sara IONESCU, Oana PATRINOIU, Mihaela ANDREESCU   +3 more
doaj   +1 more source

Success and limitations of plasma treatment in pregnant women with congenital thrombotic thrombocytopenic purpura

Journal of Thrombosis and Haemostasis, 2020
Congenital thrombotic thrombocytopenic purpura (cTTP), otherwise known as Upshaw‐Schulman syndrome, is an extremely rare hereditary disease. Pregnancy is identified as a trigger for TTP episodes in patients with cTTP.
K. Sakai, Y. Fujimura, Yasuyuki Nagata, S. Higasa, M. Moriyama, A. Isonishi, M. Konno, M. Kajiwara, Y. Ogawa, Shigehiko Kaburagi, T. Hara, K. Kokame, T. Miyata, K. Hatakeyama, M. Matsumoto   +14 more
semanticscholar   +1 more source

Disintegrin‐Like and Metalloprotease With Thrombospondin Type 1 Repeat Motifs 13 (ADAMTS13) Activity in 40 Healthy Dogs

Veterinary Clinical Pathology, EarlyView.
ABSTRACT Background In humans, deficiency of a disintegrin‐like and metalloprotease with thrombospondin type 1 motifs, number 13 (ADAMTS13), a von Willebrand factor (vWF) cleaving protease, is an underlying mechanism for thrombosis. The role of ADAMTS13 in canine thromboembolic disease is largely unknown.
Ashley R. Wilkinson, Priscila Beatriz da Silva Serpa, S. Michelle Todd   +2 more
wiley   +1 more source

Daratumumab for immune thrombotic thrombocytopenic purpura

Blood Advances, 2021
Key Points Treatment of iTTP with daratumumab leads to disappearance of ADAMTS13 inhibitor and restoration of normal ADAMTS13 activity. Targeting of plasma cells with daratumumab is a new treatment option in relapsing and refractory iTTP.
J. van den Berg, J. K. Kremer Hovinga, C. Pfleger, I. Hegemann, G. Stehle, A. Holbro, J. Studt   +6 more
semanticscholar   +1 more source

Anti‐ADAMTS13 Antibodies Trajectory is Associated With ADAMTS13 Recovery in Immune‐Mediated TTP

American Journal of Hematology, Volume 100, Issue 10, Page 1736-1746, October 2025.
Anti‐ADAMTS13 IgG antibodies titer trajectory from baseline to day 7–14 post‐TPE as a reliable approach to identify iTTP patients at risk of late response to the triplet therapy regimen. ABSTRACT Current triplet regimens associating therapeutic plasma exchange (TPE), immunosuppression with corticosteroids and rituximab, and caplacizumab have ...
Marie Robert, Arthur Mageau, Ygal Benhamou, François Provôt, Jehane Fadlallah, Lionel Galicier, Elie Azoulay, Hafid Ait‐Oufella, Tomas Urbina, Pascale Poullin, Alain Wynckel, Coralie Poulain, Nihal Martis, Pierre Perez, Virginie Rieu, Yahsou Delmas, Jean‐Michel Halimi, Christelle Barbet, Amélie Seguin, Valérie Chatelet, Jean‐François Augusto, Mathieu Legendre, Olivier Moranne, Carole Philipponnet, Bérengère Cador, Raïda Bouzid, Bérangère S. Joly, Agnès Veyradier, Paul Coppo, on behalf of the French Reference Center for Thrombotic Microangiopathies, Augusto Jean‐François, Azoulay Elie, Barbay Virginie, Benhamou Ygal, Charasse Christophe, Charvet‐Rumpler Anne, Chauveau Dominique, Ribes Davis, Choukroun Gabriel, Coindre Jean‐Philippe, Coppo Paul, Delmas Yahsou, Kwon Theresa, Salanoubat Célia, Dossier Antoine, Fain Olivier, Ville Simon, Frémeaux‐Bacchi Véronique, Galicier Lionel, Grangé Steven, Guidet Bertrand, Halimi Jean‐Michel, Hamidou Mohamed, Neel Antoine, Fornecker Luc‐Matthieu, Hié Miguel, Jacobs Frédéric, Joly Bérangère, Kanouni Tarik, Kaplanski Gilles, Rieu Claire, Le Guern Véronique, Moulin Bruno, Rebibou Jean‐Michel, Ojeda Uribe Mario, Parquet Nathalie, Pène Frédéric, Perez Pierre, Poullin Pascale, Marie Manon, Presne Claire, Provôt François, Mesnard Laurent, Saheb Samir, Seguin Amélie, Servais Aude, Stépanian Alain, Veyradier Agnès, Vigneau Cécile, Wynckel Alain, Zunic Patricia   +80 more
wiley   +1 more source

Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2‐Low Breast Cancer With Cancer‐Related Microangiopathic Hemolytic Anemia: A Case Report

Cancer Innovation, Volume 4, Issue 5, October 2025.
The diagnosis and treatment of acquired hemolytic anemia can be challenging. In breast cancer patients, it may be directly associated with the underlying malignancy (as an initial presentation or during disease progression). The diagnosis of cancer‐related microangiopathic hemolytic anemia (CR‐MAHA) is often delayed, and patients have a high mortality ...
Mengyuan Li, Mao Ding, Yukun Hou, Xuening Duan, Yuanjia Cheng, Ling Xu   +5 more
wiley   +1 more source

A rare case of hereditary thrombotic thrombocytopenic purpura in a toddler

Liječnički vjesnik, 2023
Hereditary thrombotic thrombocytopenic purpura (hTTP) is a thrombotic microangiopathy caused by pathogenic variants in the ADAMTS13 gene resulting in highly reduced activity of von Willebrand factor-cleaving metalloprotease.
Ozana Jakšić, Jana Jelčić, Maša Davidović   +2 more
doaj   +1 more source

Use of PopPK and E‐R Analyses toward Explaining Causal Link Between ADAMTS13 in Recombinant vs. Plasma‐Based Therapies and Clinical Effects in cTTP

Clinical Pharmacology &Therapeutics, Volume 118, Issue 4, Page 813-822, October 2025.
Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra‐rare, potentially life‐threatening condition caused by a deficiency of the blood enzyme ADAMTS13. Until now, ADAMTS13 replacement has been achieved with infusions of plasma or plasma‐based therapies (PBT).
Munjal Patel, Huijuan Xu, Olivier Barriere, Paul Diderichsen, Parth Patwari, Andy Z. X. Zhu, Jean François Marier, Thomas Peyret, Linda T. Wang, Björn Mellgård, Wenping Wang, Indranil Bhattacharya   +11 more
wiley   +1 more source